Abstracts tagged "Raynaud’s phenomenon"

Abstract Number: 2656 • ACR Convergence 2025
Long-term effect of selexipag in systemic sclerosis-associated digital ulcers: a case control, multicentre, observational study
Claudia Iannone¹, Marco Di Battista², Maria Rosa Pellico³, ilaria Magi⁴, Antonina Minniti⁵, Giuseppe Armentaro⁴, Silvia Cavalli⁴, Manuel Sette⁴, Laura Giudice⁴, Cristina Bochicchio⁴, Alessandra Della Rossa⁶, Antonio Gaetano Tavoni⁷, Fabio Cacciapaglia⁸, Stefano Stano⁹, Martina Orlandi¹⁰, Dilia Giuggioli¹¹, Marta Mosca¹², Roberto Caporali¹³ and Nicoletta Del pAPA³, ¹University of Milan, Gaetano Pini CTO, Milano, Milan, Italy, ²Rheumatology Unit, University of Pisa, Pisa, Italy, ³ASST Pini-CTO, Clinical Rheumatology Unit, Milano, Italy, ⁴ASST Pini-CTO, Clinical Rheumatology Unit, Milan, Italy, ⁵ASST Gaetano Pini, milano, Milan, Italy, ⁶Rheumatology Unit, University of Pisa, Milan, Italy, ⁷Clinical Immunology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Milan, Italy, ⁸Rheumatology Unit DiMePRe-J, University and AOU Policlinico of Bari & Department of Medicine LUM "G. De Gegnnaro" University, Casamassima (Bari) - Italy, Bari, Italy, ⁹⁶. Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari, Bari, Italy, ¹⁰Rheumatology Unit, Department of Medical and Surgical Sciences for Children and Adults, University Hospital of Modena and Reggio Emilia School of Medicine, Italy., modena, Italy, ¹¹Scleroderma Unit, Rheumatology Unit, University Hospital of Modena and Reggio Emilia, Modena, Italy, Modena, Italy, ¹²University of Pisa, Pisa, Pisa, Italy, ¹³University of Milan and ASST Gaetano Pini-CTO, Milano, Italy
Background/Purpose: Digital ulcers (DUs) affect approximately 50% of SSc patients, causing significant pain and disability. Current management involves both systemic and local therapies. However, the…
Abstract Number: 2493 • ACR Convergence 2025
Investigating scoring systems to measure clinically relevant changes in systemic sclerosis-related finger acro-osteolysis over time, as assessed in serial hand radiographs
Michael Hughes¹, Graham Dinsdale², Aayushi Agnihotri³, Joanne Manning², Muditha Samaranayaka⁴, Jonathan Harris² and Ariane Herrick⁵, ¹The University of Manchester, Manchester, England, United Kingdom, ²Northern Care Alliance NHS Foundation Trust, Salford, United Kingdom, ³The University of Manchester, Manchester, United Kingdom, ⁴Salford Royal Hospital, Salford, United Kingdom, ⁵The University of Manchester, UK, Aberdeen, United Kingdom
Background/Purpose: Acro-osteolysis (A-O, terminal tuft digit resorption) is characteristic of systemic sclerosis (SSc), occurring in 20-25% of patients (1). Outcome measures are much needed. Following…
Abstract Number: 1969 • ACR Convergence 2025
Enhancing Objective Evaluation of Raynaud’s in Veterans with Scleroderma-related Hand Pain: Integrating Patient Reported Outcomes and Nailfold Capillaroscopy
Genessis Maldonado¹, Sowmika Rao¹ and Tracy Frech², ¹Vanderbilt University Medical Center, Nashville, ²Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Raynaud’s phenomenon (RP) is a painful and disabling feature of systemic sclerosis (SSc) that significantly impairs quality of life. Tools that integrate subjective symptom…
Abstract Number: 1954 • ACR Convergence 2025
Revolutionizing Microvascular Screening: AI-Powered Dermatoscopy for Efficient Nailfold Capillary Evaluation
Genessis Maldonado¹, Eduardo Ramos ibáñez², Borja del Carmelo Gracia Tello³ and Tracy Frech⁴, ¹Vanderbilt University Medical Center, Nashville, ²Capillary.io, Zaragoza, Aragon, Spain, ³Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, ⁴Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Nailfold capillaroscopy plays a critical role in the diagnosis and management of systemic sclerosis (SSc) and related connective tissue diseases. However, access to capillaroscopy…
Abstract Number: 1582 • ACR Convergence 2025
Risk factors for incident digital ischemic complications in systemic sclerosis in the Collaborative National Quality and Efficacy Registry (CONQUER)
Marissa Savoie¹, Monica Harding², John VanBuren², Shervin Assassi³, Elana Bernstein⁴, Lorinda Chung⁵, Luke Evnin⁶, Tracy Frech⁷, Jessica Gordon¹, Faye Hant⁸, Laura Hummers⁹, Dinesh Khanna¹⁰, Kimberly Lakin¹, Dorota Lebiedz-Odrobina², Yiming Luo⁴, Ashima Makol¹¹, Maureen Mayes¹², Zsuzsanna McMahan¹³, Jerry Molitor¹⁴, Duncan Moore¹⁵, Carrie Richardson¹⁶, Nora Sandorfi¹⁷, Ami Shah⁹, Ankoor Shah¹⁸, Brian Skaug¹⁹, Virginia Steen²⁰, Elizabeth Volkmann²¹, Carleigh Zahn¹⁰ and Flavia Castelino²², ¹Hospital for Special Surgery, New York, NY, ²University of Utah, Salt Lake City, UT, ³Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX, ⁴Columbia University, New York, NY, ⁵Stanford University, Stanford, CA, ⁶Scleroderma Research Foundation, Brisbane, CA, ⁷Vanderbilt University Medical Center, Nashville, TN, ⁸Medical University of South Carolina, Charleston, SC, ⁹Johns Hopkins Rheumatology, Baltimore, MD, ¹⁰University of Michigan, Ann Arbor, MI, ¹¹Mayo Clinic, Rochester, MN, ¹²UT Health Houston Division of Rheumatology, Houston, TX, ¹³UT Health Houston, Houston, TX, ¹⁴University of Minnesota, Minneapolis, MN, ¹⁵Northwestern Memorial Hospital, Chicago, IL, ¹⁶Northwestern University, Chicago, IL, ¹⁷University of Pennsylvania, Philadelphia, PA, ¹⁸Duke University, Durham, NC, ¹⁹UTHealth Houston Division of Rheumatology, Houston, TX, ²⁰Georgetown University School of Medicine, Washington, DC, ²¹Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA, ²²Massachusetts General Hospital, Boston, MA
Background/Purpose: There have not been large US-based studies of digital pitting scars (DPS) and digital ischemic ulcers (DIU) in systemic sclerosis. Utilizing the Collaborative National…
Abstract Number: 0704 • ACR Convergence 2025
Human Pharmacokinetics of Inhaled Liposomal Iloprost Support a Dosing Regimen for Treating Systemic Sclerosis- Related Digital Ulcer
Pei Kan, Ko-Chieh Chen and Shin-Shin Chuang, Pharmosa Biopharm Inc, Taipei, Taiwan (Republic of China)
Background/Purpose: Iloprost is recommended and widely used in Europe for treating systemic sclerosis (SSc)-related Raynaud Phenomena (RP) and Digital Ulcer (DU). EULAR recommendation suggests continuous…
Abstract Number: 0117 • ACR Convergence 2025
Are Thrombotic or Obstetric Events Associated with Additional Clinical Domains in Triple Antiphospholypid Syndrome?
Cristina Rocamora-Gisbert¹, Francina salabert-Carreras², Raquel Ugena-García³, Cristina Calomarde-Gómez³, Clara Churtichaga Domenech², Judith Vidal-Ripoll², Laia Gifre-Sala², Agueda Prior-Español², Annika Nack¹, Susana Holgado⁴, Maria Aparicio¹, Melania Martínez-Morillo², LOURDES MATEO SORIA⁵, Anne Riveros frutos¹, Ivette Casafont-Solé³ and Judit Font-Urgelles³, ¹Hospital Germans Trias i Pujol, Barcelona, Spain, ²Hospital Germans Trias i Pujol, Barcelona, ³Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁴Hospital Germans Trias i Pujol, Barcelona, Catalonia, Spain, ⁵HOSPITAL GERMANS TRIAS I PUJOL, BADALONA, Spain
Background/Purpose: It is known that triple positive antiphospholipid syndrome (APS-TP) is related to an increased presence of thrombotic and obstetric manifestations. Triple positivity is referred…
Abstract Number: 2472 • ACR Convergence 2024
Are Anti-centromere Antibodies (aCENP) Predictive of Systemic Sclerosis Development in Patients Without Raynaud´s Phenomenon?
Andrea Alvear-Torres¹, María José Martínez-Becerra², María Carmen Vegas-Sánchez³, Sheila Recuero-Díaz¹, María Pérez-ferro⁴ and Olga Sánchez-Pernaute⁵, ¹Department of Rheumatology and Joint and Bone Research Unit. Hospital Universitario Fundación Jiménez Díaz and IIS-FJD, Madrid, Spain, ²Department of Immunology. Hospital Universitario Fundación Jiménez Díaz and IIS-FJD, Madrid, Spain, ³Hospital Universitario Fundación Jiménez Díaz and IIS-FJD, Madrid, Spain, ⁴Department of Rheumatology. Hospital Universitario Rey Juan Carlos, Madrid, Spain, ⁵Department of Rheumatology and Joint and Bone Research Unit. Hospital Universitario Fundación Jiménez Díaz and IIS-FJD. Autonomous University of Madrid, Madrid, Spain
Background/Purpose: Anti-centromere (aCENP) antibodies are considered highly specific of systemic sclerosis (SSc), typically defining a limited cutaneous phenotype, usually associated to Raynaud´s phenomenon (RP). It…
Abstract Number: 2683 • ACR Convergence 2024
Optical Coherence Angiography: A Non-invasive, Safe Method for Assessing the Systemic Sclerosis Related Vasculopathy Beyond Nailfold Capillaries
Pavel Nikitin¹, Harshdeep Chawla¹, Manmohan Singh¹, Samuel Theodore², Salavat Aglyamov¹, Meng Zhang², Brian Skaug², Maureen Mayes², Kirill Larin¹ and Shervin Assassi², ¹University of Houston, Houston, TX, ²UTHealth Houston Division of Rheumatology, Houston, TX
Background/Purpose: Vascular involvement is a prominent feature of systemic sclerosis (SSc). Safe and non-invasive methods to visualize cutaneous blood vessels beyond nailfold capillaries are lacking.…
Abstract Number: PP07 • ACR Convergence 2024
My Journey with Diffuse Scleroderma and Interstitial Lung Disease: A Pharmacist’s Perspective
Joseph Washington, Cencora, Washington, DC
Background/Purpose: Since my diagnosis with diffuse scleroderma and ILD, I have balanced the roles of patient and young pharmacist. A duality that has surely impacted…
Abstract Number: 0568 • ACR Convergence 2024
Coexistence of Raynaud’s Phenomenon, Morphea or Scleroderma in Spondyloarthritis Patients: Insights from a Retrospective Cohort Study Highlighting a Unique Phenotype
Ameesh Dev, Cary Roy, Deepak Jagannath, Alexandra Cloutet and Sarah Kazzaz, Houston Methodist Hospital, Houston, TX
Background/Purpose: Spondyloarthritis (SpA) is a heterogeneous group of inflammatory arthritides that includes ankylosing spondylitis (AS), psoriatic arthritis (PsA), enteropathic-related arthritis, reactive arthritis, and undifferentiated SpA.…
Abstract Number: 0677 • ACR Convergence 2024
Patterns of Raynaud’s Phenomenon Management in Patients with Systemic Sclerosis: A Real-World Data from Community-Based Practices in the United States
Gulsen Ozen¹, Sofia Pedro², Kaleb Michaud³ and Robyn Domsic⁴, ¹University of Nebraska Medical Center, Bellevue, NE, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³University of Nebraska Medical Center, Omaha, NE, ⁴Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA
Background/Purpose: Raynaud’s phenomenon (RP) and the complex vasculopathy of systemic sclerosis (SSc) can lead to chronic digital ischemia, ulcerations, and necrosis with significant pain and…
Abstract Number: 0679 • ACR Convergence 2024
Comparing Raynaud’s Phenomenon Measurement Tools: Results of the Optimizing Raynaud Phenomenon Outcome Measures in Systemic Sclerosis (ROSS) Study
Rachel Wallwork¹, Haomin Hu², Ami Shah³, Laura Hummers⁴, John Pauling⁵, Victoria Flower⁶, Bambang Parmanto², Andi Saptono² and Robyn Domsic⁷, ¹Johns Hopkins University, Towson, MD, ²University of Pittsburgh, Pittsburgh, PA, ³Division of Rheumatology, Johns Hopkins University, Ellicott City, MD, ⁴Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Ellicott City, MD, ⁵North Bristol NHS Trust, Bristol, United Kingdom, ⁶Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁷Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA
Background/Purpose: Raynaud’s phenomenon (RP) is the most common symptom in systemic sclerosis (SSc) and can lead to significant morbidity, including digital ulcers and/or gangrene. Despite…
Abstract Number: 0703 • ACR Convergence 2024
Preliminary Results from the RECONNOITER Trial, a Phase 2 Study of AISA 021 in the Treatment of Secondary Raynaud’s, Primarily Due to Systemic Sclerosis
Andrew Sternlicht¹, Michael Shanahan², Erin Morton², Meredith Todd³, Ivana Hunt², Zoey Reed², amanda weragoda⁴, Lashika Weerakoon² and Elizabeth Briggs², ¹Tufts University Medical Center and Aisa Pharma, Inc., Boston, MA, ²Flinders Medical Centre, Adelaide, Australia, ³Aisa Pharma Pty Ltd., East Lindfield, New South Wales, Australia, ⁴F, Adelaide, Australia
Background/Purpose: While 95% of Systemic Sclerosis (SSc) patients have Raynaud’s phenomenon(RP) and many patients rate it as the most bothersome and severe symptom of their…
Abstract Number: 1586 • ACR Convergence 2024
The Relationship Between the Presence, Quantity and Distribution of Cutaneous Telangiectasia and Other Vascular Manifestations of Systemic Sclerosis
Matthew Wells¹, Robyn Domsic², Ami Shah³, Laura Hummers⁴, Aishwarya Anilkumar¹, Tracy Frech⁵, Ariane Herrick⁶, Christopher Denton⁷, Dinesh Khanna⁸ and John Pauling¹, ¹North Bristol NHS Trust, Bristol, United Kingdom, ²Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ³Division of Rheumatology, Johns Hopkins University, Ellicott City, MD, ⁴Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Ellicott City, MD, ⁵Vanderbilt University Medical Center, Nashville, TN, ⁶University of Manchester, UK, Aberdeen, United Kingdom, ⁷University College London, Northwood, United Kingdom, ⁸University of Michigan, Ann Arbor, MI
Background/Purpose: Telangiectasia are permanently dilated dermal postcapillary venules and are the 2nd most common manifestation (~80%) of systemic sclerosis (SSc) after Raynaud’s phenomenon (RP). The…

1
2
3
…
8
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].